VERU INC. 8K

Veru Inc. announced fiscal 2026 Q3 results, full enrollment and timelines for its Phase 2b PLATEAU enobosarm/semaglutide obesity trial, and receipt of a USPTO Notice of Allowance for a key U.S. patent expected to protect this combination therapy until at least October 2044.

On August 10, 2026, Veru Inc. reported its fiscal 2026 third quarter financial results and provided a clinical and intellectual property update, highlighting that its Phase 2b PLATEAU trial evaluating enobosarm in combination with semaglutide for higher quality weight loss in older obese patients is now fully enrolled with 239 patients and remains on track for an interim analysis in the first quarter of calendar 2027 and final topline data in the fourth quarter of 2027, while also noting a previously announced clinical supply agreement with Novo Nordisk for this trial and a recent USPTO Notice of Allowance for a key U.S. patent covering enobosarm/semaglutide combination regimens expected to provide patent protection until at least October 3, 2044, alongside reporting a quarterly net loss of $7.0 million and cash, cash equivalents and restricted cash of $23.9 million as of June 30, 2026.

Filing Facts

CIK

863894

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-341187

Alert Tier

6